“farmaci innovativi, biotecnologici e terapie … · “farmaci innovativi, biotecnologici e...
TRANSCRIPT
![Page 1: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/1.jpg)
“FARMACIINNOVATIVI,BIOTECNOLOGICIETERAPIESTAMINALI:FARMACOLOGIA,FARMACOTERAPIAENORMATIVE”
Roma, 14 aprile 2015
Farmacibiotecnologici:FarmacologiaeFarmacoterapia
PierluigiNavarra
![Page 2: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/2.jpg)
Farmaco Biotecnologico: esempi
OrmoniInsulina umanaricombinante
ProteineEritropoietina umanaricombinante
Fattori di crescitaGCSF (Granulocyte colony‐stimulating factor) umanoricombinante
Anticorpi monoclonali
Infliximab(CHIMERICO)
Bevacizumab(UMANIZZATO)
Adalimumab(UMANO)
Proteine di Fusione
Etanercept
![Page 3: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/3.jpg)
Simple(e.g. omnitrope – hGH)
Complex(e.g. Herceptin - MAb)
Small molecule(e.g. fluoxetine)
Characteristics:
• Size:
• Structure:
• Stability:
• Modification:
• Characterization:
Manufacturing:
Development:
Regulation:
• Small
• Simple
• Stable
• Well-defined
• Fully characterized
• Predictable chemical process that can be copied
• Limited clinical trials (Phase I PK/PD studies)
• Interchangeable status with abbreviated procedures in US/EU
• Large
• Complex
• Unstable
• Modifiable
• Not fully characterized
• Produced in living organisms─ Highly sensitive to
manufacturing changes
─ High fixed investment
• Significant R&D (cell lines)
• Extensive clinical trials (Phase I and III)
• Pathway defined by EMEAbased on comparable status
• No US pathway under BLA
Chemical Biologics
• Greater likelihood of post-translational modification
– Phosphorylation
– Glycosylation
– Acetylation
• Impacts 3D structure, and:– Activity / stability
– Immunogenicity
• Increased costs/risks:– Complex manufacturing
– Regulatory scrutiny
– Higher burden of proof
• Higher costs reduce number of potential market entrants
– Revenue potential increases with complexity
![Page 4: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/4.jpg)
![Page 5: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/5.jpg)
![Page 6: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/6.jpg)
Key‐words importanti: ‘hybridoma’
![Page 7: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/7.jpg)
EQ -1
EQ -1
Farmaco purificato
Fase Operativa Specificità di Prodotto
Espansione cellulare Linea cellulare, terreno di coltura, metodo di espansione
Produzione cellulare nel bioreattore
Linea cellulare, terreno di coltura, condizioni del bioreattore
Recupero per filtrazione o centrifugazione
Condizioni operative diverse
Purificazione per cromatografia
Diverse condizioni di legame ed eluzione cromatografica
Caratterizzazione e stabilità
Differenze di metodi, reagenti e standard di riferimento
Lo scale‐up alla produzione industriale: “il processo è il prodotto” KL Karson, Nature biotechnology 2005
![Page 8: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/8.jpg)
Key‐words importanti: ‘phage display library’
![Page 9: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/9.jpg)
Categorie di anticorpi monoclonali
“‐omab” “‐ximab” “‐zumab” “‐mumab”
![Page 10: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/10.jpg)
Anticorpi completi e frammenti..
![Page 11: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/11.jpg)
Un esempiodi un frammento diventato famoso…
![Page 12: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/12.jpg)
• Monovalent (one‐armed), monoclonal antibody designed to bind to MET and inhibitHepatocyte Growth Factor / Scatter Factor (HGF/SF) binding
• Traditional bivalent antibodies to MET potentially activate, rather than inhibit, MET signaling by inducing MET dimerization.
• In contrast, the monovalent design of onartuzumab inhibits HGF/SF binding withoutinducing MET dimerization.
• Onartuzumab has demonstrated antitumor activity in preclinical analyses and under evaluation in phase III clinical trials for NSCLC and GC
![Page 13: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/13.jpg)
![Page 14: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/14.jpg)
Schema generale dello sviluppodi un MoAB
![Page 15: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/15.jpg)
Un esempio di ‘clinically validated target’
![Page 16: “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE … · “FARMACI INNOVATIVI, BIOTECNOLOGICI E TERAPIE STAMINALI: FARMACOLOGIA, FARMACOTERAPIA E NORMATIVE” ... reagenti e standard](https://reader030.vdocumenti.com/reader030/viewer/2022021722/5c6848dc09d3f263648b471b/html5/thumbnails/16.jpg)